Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

RECRUITING

Identifier: CI-TRIAL-00111422
Entity page: /trial/NCT06948084 ↗
Edges: 6

Neighbours: 1 cancers4 drugs
Drawn: 5 of 5 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse condition of …CONDITION_OFderived2 of 2
← condition of	Multiple Myeloma registry condition “Recurrent Multiple Myeloma” mapped CURATED_BROADER	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
← condition of	Multiple Myeloma registry condition “Refractory Multiple Myeloma” mapped CURATED_BROADER

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse intervention of …INTERVENTION_OFderived4 of 4
← intervention of	Carfilzomibother registry intervention “Carfilzomib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Dexamethasonesmall molecule registry intervention “Dexamethasone” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pomalidomidesmall molecule registry intervention “Pomalidomide” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Teclistamabmonoclonal antibody registry intervention “Teclistamab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse intervention of …INTERVENTION_OFderived4 of 4

← intervention of

Carfilzomibother

registry intervention “Carfilzomib” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Dexamethasonesmall molecule

registry intervention “Dexamethasone” (DRUG) mapped ALIAS

—